Neither the bavi phase 2a first-line NSCLC, or the other trial I used for control comparison (TLF), excluded patients with squamous cell cancer. The bavi trial had 8/49 (16%) patients with squamous cell NSCLC, as seen in the patient demographics in my post. The other trial did not list the cell types. The Avastin first-line NSCLC trial excluded patients with squamous cell cancer